Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Innate Pharma's price to sales ratio was 14.2× on Nov 11, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 1.9× to 18.6×, with a median of 6.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 14.2× | +8.2 |
| 2025 | Dec 31, 2025 | 6.0× | +3.7 |
| 2024 | Dec 31, 2024 | 2.3× | −1.2 |
| 2023 | Dec 29, 2023 | 3.5× | −7.7 |
| 2022 | Dec 30, 2022 | 11.2× | +6.7 |
| 2021 | Dec 31, 2021 | 4.6× | +1.9 |
| 2020 | Dec 31, 2020 | 2.6× | −1.0 |
| 2019 | Dec 31, 2019 | 3.6× | – |
See a number that looks wrong?